Global Cardiac Markers Rapid Tests and POC Pipeline Report 2022 - Featuring 1Drop Diagnostics, Abbott Point of Care and Accel Diagnostics Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cardiac Markers Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive information about the Cardiac Markers Rapid Tests & POC pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Cardiac Markers Rapid Tests & Point of Care (POC) are rapid diagnostic tests which are simple to perform, ready to use, accurate, economic and for infield use suggested for individuals suspected with any indication.

Scope

• Extensive coverage of the Cardiac Markers Rapid Tests & POC under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Cardiac Markers Rapid Tests & POC and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Cardiac Markers Rapid Tests & POC under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

2 Introduction

2.1 Cardiac Markers Rapid Tests & POC Overview

3 Products under Development

3.1 Cardiac Markers Rapid Tests & POC - Pipeline Products by Stage of Development

3.2 Cardiac Markers Rapid Tests & POC - Pipeline Products by Segment

3.3 Cardiac Markers Rapid Tests & POC - Pipeline Products by Territory

3.4 Cardiac Markers Rapid Tests & POC - Pipeline Products by Regulatory Path

3.5 Cardiac Markers Rapid Tests & POC - Pipeline Products by Estimated Approval Date

4 Cardiac Markers Rapid Tests & POC - Pipeline Products under Development by Companies

4.1 Cardiac Markers Rapid Tests & POC Companies - Pipeline Products by Stage of Development

4.2 Cardiac Markers Rapid Tests & POC - Pipeline Products by Stage of Development

5 Cardiac Markers Rapid Tests & POC Companies and Product Overview

6 Cardiac Markers Rapid Tests & POC- Recent Developments

6.1 Dec 15, 2021: Trinity Biotech Announces Q3 2021 Results, the Entry Into a $81,250,000 Loan Facility to Refinance the Company's Exchangeable Senior Notes and Agreements To Repurchase Outstanding Exchangeable Senior Notes

6.2 Sep 01, 2021: BioMerieux announce First-Half 2021 Results

6.3 Jul 16, 2021: Trinity Biotech Provides a Business Development Update For Q2 2021

7 Appendix

Companies Mentioned

• 1Drop Diagnostics
• Abbott Point of Care Inc
• Accel Diagnostics LLC
• Alfa Wassermann Inc
• Angle Biosciences Inc
• Anteo Technologies Pty Ltd
• Atonomics A/S (Inactive)
• Axis-Shield Diagnostics Ltd
• BBB Technologies Inc
• Bio-AMD Inc
• BiOracle Ltd (Inactive)
• Biosensia Ltd
• Biostealth, Inc.
• Biosurfit, SA
• Bluejay Diagnostics Inc
• Boditech Med Inc
• Carclo Diagnostic Solutions Ltd
• CardioGenics Inc
• Coris BioConcept
• Diazyme Laboratories Inc
• Duke University
• Dynasil Corporation of America
• Eachy Biopharmaceuticals Ltd
• ET Healthcare Inc
• genedrive plc
• Group K Diagnostics
• LeukoDx Ltd
• LumiraDx Ltd
• Maxim Biomedical Inc
• MML Ltd
• Mylab Discovery Solutions Pvt Ltd
• MyMD Pharmaceuticals, Inc
• Nanomix Inc
• Novartis AG
• Ohmx Corp
• OPKO Health Inc
• Proxim Diagnostics Corp
• Radiometer Medical ApS
• Radisens Diagnostics Ltd
• Resdin Technologies Inc.
• Salignostics Ltd
• Sandia National Laboratories
• Sarissa-Biomedical Ltd
• SpinChip Diagnostics AS
• Thermo Fisher Scientific Inc
• ThreeFold Sensors (Inactive)
• Trinity Biotech Plc
• True Diagnostics Inc
• Upstream Medical Technologies Ltd

For more information about this report visit https://www.researchandmarkets.com/r/kzfj9s

Source: GlobalData